These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 35626057)
1. P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs. Treppiedi D; Marra G; Di Muro G; Esposito E; Barbieri AM; Catalano R; Mangili F; Bravi F; Locatelli M; Lania AG; Ferrante E; Indirli R; Nozza E; Arlati F; Spada A; Arosio M; Mantovani G; Peverelli E Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626057 [TBL] [Abstract][Full Text] [Related]
2. Improved pasireotide response in USP8 mutant corticotroph tumours in vitro. Albani A; Perez-Rivas LG; Tang S; Simon J; Lucia KE; Colón-Bolea P; Schopohl J; Roeber S; Buchfelder M; Rotermund R; Flitsch J; Thorsteinsdottir J; Herms J; Stalla G; Reincke M; Theodoropoulou M Endocr Relat Cancer; 2022 Aug; 29(8):503-511. PubMed ID: 35686696 [TBL] [Abstract][Full Text] [Related]
3. Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel Treppiedi D; Barbieri AM; Di Muro G; Marra G; Mangili F; Catalano R; Esposito E; Ferrante E; Serban AL; Locatelli M; Lania AG; Spada A; Arosio M; Peverelli E; Mantovani G Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439178 [TBL] [Abstract][Full Text] [Related]
4. USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs. Treppiedi D; Di Muro G; Marra G; Barbieri AM; Mangili F; Catalano R; Serban A; Ferrante E; Locatelli M; Lania AG; Arosio M; Spada A; Peverelli E; Mantovani G Endocr Relat Cancer; 2021 Jun; 28(8):573-582. PubMed ID: 34086599 [TBL] [Abstract][Full Text] [Related]
5. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease. Hayashi K; Inoshita N; Kawaguchi K; Ibrahim Ardisasmita A; Suzuki H; Fukuhara N; Okada M; Nishioka H; Takeuchi Y; Komada M; Takeshita A; Yamada S Eur J Endocrinol; 2016 Feb; 174(2):213-26. PubMed ID: 26578638 [TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations. Peverelli E; Treppiedi D; Mantovani G Endocr Oncol; 2022 Jan; 2(1):R24-R30. PubMed ID: 37435448 [TBL] [Abstract][Full Text] [Related]
7. Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease. Weigand I; Knobloch L; Flitsch J; Saeger W; Monoranu CM; Höfner K; Herterich S; Rotermund R; Ronchi CL; Buchfelder M; Glatzel M; Hagel C; Fassnacht M; Deutschbein T; Sbiera S J Clin Endocrinol Metab; 2019 Jul; 104(7):2535-2546. PubMed ID: 30844069 [TBL] [Abstract][Full Text] [Related]
8. Targeted analysis of Ubiquitin-Specific Peptidase (USP8) in a population of Iranian people with Cushing's disease and a systematic review of the literature. Hashemi-Madani N; Cheraghi S; Emami Z; Mehrjardi AZ; Kaynama MR; Khamseh ME BMC Endocr Disord; 2024 Jun; 24(1):86. PubMed ID: 38862897 [TBL] [Abstract][Full Text] [Related]
10. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells. Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo. Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056 [TBL] [Abstract][Full Text] [Related]
17. Recurrent gain-of-function USP8 mutations in Cushing's disease. Ma ZY; Song ZJ; Chen JH; Wang YF; Li SQ; Zhou LF; Mao Y; Li YM; Hu RG; Zhang ZY; Ye HY; Shen M; Shou XF; Li ZQ; Peng H; Wang QZ; Zhou DZ; Qin XL; Ji J; Zheng J; Chen H; Wang Y; Geng DY; Tang WJ; Fu CW; Shi ZF; Zhang YC; Ye Z; He WQ; Zhang QL; Tang QS; Xie R; Shen JW; Wen ZJ; Zhou J; Wang T; Huang S; Qiu HJ; Qiao ND; Zhang Y; Pan L; Bao WM; Liu YC; Huang CX; Shi YY; Zhao Y Cell Res; 2015 Mar; 25(3):306-17. PubMed ID: 25675982 [TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity. Treppiedi D; Giardino E; Catalano R; Mangili F; Vercesi P; Sala E; Locatelli M; Arosio M; Spada A; Mantovani G; Peverelli E Mol Cell Endocrinol; 2019 Mar; 483():31-38. PubMed ID: 30611770 [TBL] [Abstract][Full Text] [Related]
19. A long-term prognosis study of human USP8-mutated ACTH-secreting pituitary neuroendocrine tumours. Miao H; Wang L; Gong F; Duan L; Wang L; Yao Y; Feng M; Deng K; Wang R; Xiao Y; Ling Q; Zhu H; Lu L Clin Endocrinol (Oxf); 2024 Jul; 101(1):32-41. PubMed ID: 38691659 [TBL] [Abstract][Full Text] [Related]
20. [Medical Therapies in Functioning Pituitary Neuroendocrine Tumors(PitNETs)]. Nagamine T; Fukuda I No Shinkei Geka; 2023 Jul; 51(4):706-715. PubMed ID: 37491068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]